35 results
8-K
EX-99.1
u5bz1qvt ar7pu
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
8-K
EX-99.1
7mdget
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
kr85rsg
13 Mar 20
Regulation FD Disclosure
9:06am
8-K
EX-99.1
i3wi3njxh
2 Mar 20
Regulation FD Disclosure
3:48pm
424B5
i6z42
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
3yxigoyhid
7 Oct 19
Prospectus supplement for primary offering
9:33pm
424B5
6y9voc ypv
3 Oct 19
Prospectus supplement for primary offering
4:11pm
424B5
4er4ts n6z
3 Oct 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
63tyza58gwy
12 Sep 19
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome
8:10am
8-K
EX-99.1
hisn58
9 Sep 19
Other Events
12:00am
8-K
EX-99.1
ao0wxg
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
EX-99.1
q4arnr02
27 Jun 19
Other Events
8:05am